• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Immunocompromised patients have been neglected in COVID-19 trials: a call for action.免疫功能低下的患者在新冠病毒疾病试验中被忽视：呼吁采取行动。
Clin Microbiol Infect. 2022 Sep;28(9):1182-1183. doi: 10.1016/j.cmi.2022.05.005. Epub 2022 May 25.
2
COVID-19 in Elderly, Immunocompromised or Diabetic Patients-From Immune Monitoring to Clinical Management in the Hospital.COVID-19 与老年、免疫功能低下或糖尿病患者——从免疫监测到医院内的临床管理。
Viruses. 2022 Apr 1;14(4):746. doi: 10.3390/v14040746.
3
Prolonged viral shedding of SARS-CoV-2 in two immunocompromised patients, a case report.两名免疫功能低下患者的 SARS-CoV-2 病毒持续排出：病例报告
BMC Infect Dis. 2021 Aug 3;21(1):743. doi: 10.1186/s12879-021-06429-5.
4
SARS-CoV-2 late shedding may be infectious between immunocompromised hosts.SARS-CoV-2 晚期脱落物在免疫功能低下宿主之间可能具有传染性。
Infect Dis (Lond). 2021 Nov;53(11):880-882. doi: 10.1080/23744235.2021.1939891. Epub 2021 Jun 17.
5
A Short Series of Case Reports of COVID-19 in Immunocompromised Patients.免疫功能低下患者 COVID-19 的短篇病例报告系列。
Viruses. 2022 Apr 29;14(5):934. doi: 10.3390/v14050934.
6
COVID-19 in an immunocompromised host: persistent shedding of viable SARS-CoV-2 and emergence of multiple mutations: a case report.免疫功能低下宿主中的 COVID-19：活 SARS-CoV-2 的持续排出和多种突变的出现：一例报告。
Int J Infect Dis. 2022 Jan;114:178-182. doi: 10.1016/j.ijid.2021.10.045. Epub 2021 Oct 29.
7
Genomic Evolution of SARS-CoV-2 Virus in Immunocompromised Patient, Ireland.爱尔兰免疫功能低下患者体内 SARS-CoV-2 病毒的基因组进化。
Emerg Infect Dis. 2021 Sep;27(9):2499-2501. doi: 10.3201/eid2709.211159. Epub 2021 Jun 23.
8
Persistent Coronavirus Disease 2019 (COVID-19) in an Immunocompromised Host Treated by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Monoclonal Antibodies.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）特异性单克隆抗体治疗免疫功能低下宿主的持续性2019冠状病毒病（COVID-19）
Clin Infect Dis. 2022 May 3;74(9):1706-1707. doi: 10.1093/cid/ciab868.
9
Emergence of SARS-CoV-2 Spike Mutations during Prolonged Infection in Immunocompromised Hosts.免疫功能低下宿主体内 SARS-CoV-2 刺突突变的长期感染中出现。
Microbiol Spectr. 2022 Jun 29;10(3):e0079122. doi: 10.1128/spectrum.00791-22. Epub 2022 May 11.
10
Factors that predict severity of infection and seroconversion in immunocompromised children and adolescents with COVID-19 infection.预测感染新型冠状病毒肺炎（COVID-19）的免疫功能低下儿童和青少年感染严重程度及血清转化的因素。
Front Immunol. 2022 Aug 3;13:919762. doi: 10.3389/fimmu.2022.919762. eCollection 2022.

引用本文的文献

1
The Application of Single-Cell Technologies for Vaccine Development Against Viral Infections.单细胞技术在抗病毒感染疫苗研发中的应用
Vaccines (Basel). 2025 Jun 26;13(7):687. doi: 10.3390/vaccines13070687.
2
The DESTINIES Study: an online Delphi study to build international consensus on the medical conditions and procedures that confer immunosuppression and their respective COVID-19 risk profiles.DESTINIES研究：一项在线德尔菲研究，旨在就导致免疫抑制的医疗状况和程序及其各自的COVID-19风险概况达成国际共识。
EClinicalMedicine. 2025 May 5;83:103239. doi: 10.1016/j.eclinm.2025.103239. eCollection 2025 May.
3
Populations Addressed in Vaccines Approved via the European Medicines Agency.通过欧洲药品管理局批准的疫苗所针对的人群。
Clin Pharmacol Ther. 2025 Aug;118(2):459-469. doi: 10.1002/cpt.3694. Epub 2025 May 5.
4
Early combined therapy for COVID-19 in immunocompromised patients: a promising approach against viral persistence and drug resistance.免疫功能低下患者COVID-19的早期联合治疗：对抗病毒持续存在和耐药性的一种有前景的方法。
BMC Infect Dis. 2025 Apr 28;25(1):616. doi: 10.1186/s12879-025-11012-3.
5
Adverse events associated with monoclonal antibodies used for treatment of COVID-19: A systematic review and meta-analysis.与用于治疗COVID-19的单克隆抗体相关的不良事件：一项系统评价和荟萃分析。
Br J Clin Pharmacol. 2025 May;91(5):1306-1321. doi: 10.1002/bcp.70025. Epub 2025 Mar 6.
6
A third COVID-19 vaccine dose in kidney transplant recipients induces antibody response to vaccine and Omicron variants but shows limited Ig subclass switching.肾移植受者接种第三剂新冠病毒疫苗可诱导对疫苗和奥密克戎变异株的抗体反应，但免疫球蛋白亚类转换有限。
Microbiol Spectr. 2025 Mar 4;13(3):e0219024. doi: 10.1128/spectrum.02190-24. Epub 2025 Jan 31.
7
Limited Short-Term Evolution of SARS-CoV-2 RNA-Dependent RNA Polymerase under Remdesivir Exposure in Upper Respiratory Compartments.在瑞德西韦作用下，上呼吸道中 SARS-CoV-2 RNA 依赖性 RNA 聚合酶的短期进化受限。
Viruses. 2024 Sep 24;16(10):1511. doi: 10.3390/v16101511.
8
Propensity Score Methods for Confounding Control in Observational Studies of Therapeutics for COVID-19 Infection.用于COVID-19感染治疗观察性研究中混杂因素控制的倾向评分方法
Clin Infect Dis. 2024 Dec 13;79(Supplement_4):S131-S136. doi: 10.1093/cid/ciae516.
9
Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection.免疫功能低下宿主持续性 SARS-CoV-2 感染的晚期抗病毒治疗效果。
J Virol. 2024 Sep 17;98(9):e0090524. doi: 10.1128/jvi.00905-24. Epub 2024 Aug 29.
10
Charting a course for global progress in PIDs by 2030 - proceedings from the IPOPI global multi-stakeholders' summit (September 2023).绘制到 2030 年全球 PID 进展的路线图——来自 IPOPI 全球利益相关者峰会的会议记录（2023 年 9 月）。
Front Immunol. 2024 Jun 27;15:1430678. doi: 10.3389/fimmu.2024.1430678. eCollection 2024.

本文引用的文献

1
De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report.免疫功能低下患者持续性 SARS-CoV-2 感染治疗过程中雷米昔韦耐药突变的从头出现：一例病例报告。
Nat Commun. 2022 Mar 17;13(1):1547. doi: 10.1038/s41467-022-29104-y.
2
Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2.抗病毒药物对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎亚型BA.2的疗效
N Engl J Med. 2022 Apr 14;386(15):1475-1477. doi: 10.1056/NEJMc2201933. Epub 2022 Mar 9.
3
Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis.新冠疫苗在免疫功能低下患者中的有效性：系统评价和荟萃分析。
BMJ. 2022 Mar 2;376:e068632. doi: 10.1136/bmj-2021-068632.
4
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.奈玛特韦片/利托那韦片组合包装口服药用于伴有进展为重症高风险因素的 COVID-19 门诊患者。
N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16.
5
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.瑞德西韦早期治疗可降低门诊患者重症 COVID-19 进展风险
N Engl J Med. 2022 Jan 27;386(4):305-315. doi: 10.1056/NEJMoa2116846. Epub 2021 Dec 22.
6
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.Sotrovimab 对 SARS-CoV-2 中和抗体用于治疗新型冠状病毒早期感染。
N Engl J Med. 2021 Nov 18;385(21):1941-1950. doi: 10.1056/NEJMoa2107934. Epub 2021 Oct 27.
7
SARS-CoV-2 evolution during treatment of chronic infection.慢性感染治疗过程中 SARS-CoV-2 的进化。
Nature. 2021 Apr;592(7853):277-282. doi: 10.1038/s41586-021-03291-y. Epub 2021 Feb 5.

Immunocompromised patients have been neglected in COVID-19 trials: a call for action.

作者信息

Trøseid Marius, Hentzien Maxime, Ader Florence, Cardoso Sandra Wagner, Arribas Jose R, Molina Jean-Michel, Mueller Nicolas, Hites Maya, Bonnet Fabrice, Manuel Oriol, Costagliola Dominique, Grinsztejn Beatriz, Olsen Inge Christoffer, Yazdapanah Yazdan, Calmy Alexandra

机构信息

Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Oslo, Norway.

HIV/AIDS Research Unit, Geneva University Hospitals, Geneva, Switzerland.

出版信息

Clin Microbiol Infect. 2022 Sep;28(9):1182-1183. doi: 10.1016/j.cmi.2022.05.005. Epub 2022 May 25.

DOI:10.1016/j.cmi.2022.05.005
PMID:35623577
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9130310/
Abstract
摘要